DEA and FDA Issue Joint Industry Guidance on Hemp-CBD Product Regulatory Boundaries

The Drug Enforcement Administration and the Food and Drug Administration issued the first joint federal guidance document specifically addressing hemp-CBD product regulatory boundaries in December 2024. The joint guidance emerged from Congressional pressure following the 2023 hemp rider in the Consolidated Appropriations Act directing FDA and DEA to develop a unified regulatory framework for hemp-derived cannabinoids. While not legally binding, joint guidance from both agencies signals a unified federal enforcement posture. The guidance addresses three categories: (1) hemp-derived CBD in ingestible products — FDA retains primary regulatory jurisdiction; DEA confirms that CBD products meeting Farm Bill specifications are not scheduled controlled substances; (2) broad-spectrum hemp extracts containing trace delta-9 THC — DEA clarifies that products at or below 0.3% delta-9 THC by dry weight remain within the Farm Bill exemption; (3) novel cannabinoids derived via chemical synthesis — DEA reaffirms its position that chemically synthesized cannabinoids including THCO, HHCO, and similar compounds are Schedule I regardless of hemp origin. The guidance does not resolve the ingestible CBD product approval pathway under FDA's drug exclusion rule — the most significant outstanding regulatory question for the hemp-CBD industry. FDA indicates a separate notice-and-comment process is forthcoming for that issue.